Fighting antimicrobial resistance in sexually transmitted infections with targeted diagnostics
Described as the hidden pandemic, antimicrobial resistance is viewed by many scientists as one of the greatest challenges facing healthcare today and in the future. This was especially highlighted in a recent study published in The Lancet, which found antimicrobial resistance to be the direct cause of at least 1.27 million deaths globally in 2019.
While researchers are developing therapeutics to combat rapidly developing resistance across bacterial species, they now realize that it is equally important to quickly diagnose resistant infections in order to deliver the right treatment, thereby minimizing the risk of generating further resistance.
In this SelectScience webinar, three experts in their fields discuss how they were able to combine their expertise to deliver a resistance-guided therapy approach for the successful treatment and management of sexually transmitted infections (STIs), particularly in Mycoplasma genitalium.
Key learning objectives
- Acquire new diagnostic approaches to combatting antimicrobial resistance
- Learn what sort of clinical outcomes can be expected by introducing resistance-guided therapy
- Discover the advantages of taking a multiplex approach to STI diagnostics
- Explore the future for antimicrobial resistance stewardship enabled by resistance-guided therapy
Who should attend?
- Researchers and clinicians working in the field of sexual and public health
- Molecular diagnostic manufacturers working in the field of infectious disease
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
